Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 119, Issue 4, Pages 757-764Publisher
WILEY
DOI: 10.1002/ijc.21932
Keywords
curcumin; mTOR; S6K1; 4E-BP1; Akt; apoptosis; motility; rhabdomyosarcoma
Categories
Ask authors/readers for more resources
Curcumin (diferuloylmethane), a polyphenol natural product of the plant Curcuma longa, is undergoing early clinical trials as a novel anticancer agent. However, the anticancer mechanism of curcumin remains to be elucidated. Here we show that curcumin inhibited growth of rhabdomyosarcoma cells (Rh1 and Rh30) (IC50 = 2-5 mu M) and arrested cells in G(1) phase of the cell cycle. Curcumin also induced apoptosis and inhibited the basal or type I insulin-like growth factor-induced motility of the cells. At physiological concentrations (similar to 2.5 mu M). curcumin rapidly inhibited phosphorylation of the mammalian target of rapamycin (mTOR) and kits downstream effector molecules. p70 S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1). in a panel of cell lines (Rh1, Rh30, DU145. MCF-7 and Hela). Curcumin also inhibited phosphorylation of Akt in the cells. but only at high concentrations (> 40 mu M). The data suggest that curcumin may execute its anticancer activity primarily by blocking mTOR-mediated signaling pathways in the tumor cells. (c) 2006 Wiley-Liss, Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available